Xeris Biopharma Holdings (XERS) Net Income towards Common Stockholders (QoQ) (2020 - 2026)
Xeris Biopharma Holdings (XERS) Net Income towards Common Stockholders (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,492.17% |
| Mar 31, 2026 | -79.84% |
| Dec 31, 2025 | 1,684.38% |
| Sep 30, 2025 | 132.21% |
| Jun 30, 2025 | 79.09% |
| Mar 31, 2025 | -80.32% |
| Dec 31, 2024 | 67.51% |
| Sep 30, 2024 | -4.89% |
| Jun 30, 2024 | 20.94% |
| Mar 31, 2024 | -41.75% |
| Dec 31, 2023 | -9.85% |
| Sep 30, 2023 | 38.57% |
| Jun 30, 2023 | -17.87% |
| Mar 31, 2023 | -30.19% |
| Dec 31, 2022 | 40.77% |
| Sep 30, 2022 | 16.63% |
| Jun 30, 2022 | 22.33% |
| Mar 31, 2022 | 33.62% |
| Dec 31, 2021 | -95.28% |
| Sep 30, 2021 | 5.47% |